Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Clinical trial NCT07543783 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07543783
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Adebrelimab (SHR-1316)Bevacizumab Hepatocellular Carcinoma (HCC)

Start date: 2026-04-10
Primary completion: 2029-08-31
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.